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A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15mgkg
 1, capecitabine
1300mgm
 2 daily for 2 weeks and gemcitabine 1000mgm
 2 weekly 2 times; cycles were repeated every 21 days. Radiological
response rate was 22%; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities
included neutropaenia (22%), thrombocytopaenia (14%), thromboembolic events (12%), hypertension (8%) and haemorrhage (6%).
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Metastatic pancreatic cancer is one of the most chemotherapy-
resistant tumours. Gemcitabine is the chemotherapeutic agent of
choice. However, gemcitabine results in a clinical benefit response
rate (RR) of 24% and a 1-year survival of 18% only for patients
with advanced pancreatic cancer (Burris III et al, 1997). The
addition of other cytotoxic agents to gemcitabine including
capecitabine, cisplatin, irinotecan and oxaliplatin does not lead
to any improvement in overall survival (OS) (Rocha Lima et al,
2004; Louvet et al, 2005; Heinemann et al, 2006; Herrmann et al,
2007). However, gemcitabine-based combinations may have value
in patients with good performance status (PS). Recently,
Herrmann et al (2007) reported that pancreatic cancer patients
with good PS may experience improved OS and progression-free
survival (PFS) with gemcitabineþcapecitabine as compared with
gemcitabine alone. The vascular endothelial growth factor (VEGF)
is a potent angiogenic factor and represents a therapeutic target in
pancreatic cancer (Ferrara et al, 2003). Increased VEGF expression
occurs in most human tumours including pancreatic cancer
(Yoshiji et al, 1996; Soh et al, 2000; Huang et al, 2001; Deryugina
et al, 2002; Bremnes et al, 2006; Ozdemir et al, 2006; Black and
Dinney, 2007). Bevacizumab (rhuMAb VEGF) is a recombinant
humanised anti-human VEGF monoclonal antibody, which results
in a synergistic anti-tumour effect in preclinical studies when
combined with fluoropyrimidines or gemcitabine (Margolin et al,
2001; az-Rubio and Schmoll, 2005; Kindler et al, 2005a). The
present study explored the clinical activity of gemcitabine,
capecitabine and bevacizumab in patients with advanced pancrea-
tic cancer.
PATIENT ELIGIBILITY
All patients provided written informed consent before study
enrollment. Adult patients with previously untreated metastatic or
locally advanced unresectable pancreatic cancer, Eastern Coopera-
tive Oncology Group (ECOG) PS of 0 or 1, normal blood counts
(leucocytes43000 per ml, neutrophils41500 per ml, plate-
lets4100000 per ml) and chemistries (bilirubino2mg per
100ml, AST/ALTo5 times upper limits of normal, creatini-
neo1.5mg per 100ml) were included. Prior adjuvant therapy
was permitted if completed 46 months before enrollment.
Exclusion criteria included proteinuria, pregnancy, lactation,
bleeding diathesis, uncontrolled hypertension or cardiovascular
disease, brain metastases or recent surgery.
TREATMENT PLAN
Gemcitabine was administered in a dose of 1000mgm
 2
intravenously over 30min on days 1 and 8; capecitabine
650mgm
 2 twice daily was administered on days 1–14 and
bevacizumab 15mgkg
 1 was administered after gemcitabine on
day 1 of a 21-day cycle. Treatment was continued until disease
progression, death or toxicity. A maximum of 1 year of
bevacizumab therapy was permitted. However, patients could
receive gemcitabine and capecitabine beyond 1 year if indicated.
Institutional review board approval was obtained for this study.
DOSE ADJUSTMENTS
Dose reductions for gemcitabine and capecitabine were based on
manufacturer guidelines. Adverse events were graded according to
National Cancer Institute, Common Toxicity Criteria, version 3.0
(NCI-CTC v 3.0). A cycle was not started until the absolute
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sneutrophil count was 41500 per ml and platelet count was
4100000 per ml. Dose adjustments for gemcitabine were based on
the laboratory and clinical findings on the scheduled day of
administration, whereas the dose adjustment of capecitabine was
based on the toxicities during the preceding cycle. There were no
dose adjustments for bevacizumab in this study. Bevacizumab
was held for grade 3 hypertension, grade 3 thrombosis, grade 3
haemorrhage or proteinuria X2g, until resolution. Bevacizumab
was permanently discontinued for grade 4 or recurrent grade 3
vascular events. Routine use of neutrophilic growth factors was not
recommended.
STUDY EVALUATIONS
Pretreatment included complete history and physical exam,
complete blood count, chemistry including liver function tests,
prothrombin time, pregnancy test for women and 12-lead
electrocardiography. Urine protein/creatinine ratio was measured
at baseline and every 6 weeks. History and physical exam were
performed every 3 weeks. Complete blood count, serum CA 19-9
level and serum chemistries (including liver function tests) were
measured on day 1 of each treatment cycle. Computed tomo-
graphy scans to assess tumour size and response were obtained
every 6 weeks.
The PFS was defined as the length of time during and after
treatment in which the patient remained alive with cancer without
disease progression. Overall survival was defined as the time from
treatment initiation until demise. Responses were estimated using
the response evaluation criteria in solid tumors (RECIST)
(Therasse et al, 2000). CA 19-9 improvement by 50% was defined
as a ‘CA 19-9 response’.
STATISTICS
The primary study aim was evaluation of PFS with the combina-
tion therapy for patients with pancreatic cancer. Secondary aims
were estimation of RR, toxicity and OS. We calculated 95%
confidence intervals for estimated PFS and OS curves using the
Greenwood formula. The sample size was calculated to provide
estimations of median PFS and median OS with reasonable
accuracy. The projected 95% confidence interval width with 50
patients was approximately 3.5 months. The survival curves for
OS and PFS were estimated by the Kaplan–Meier method.
The Clopper–Pearson method was used to estimate the 95%
confidence interval for the RR.
The association of survival and quantifiable variables, including
age, grade and CA 19-9 level, was univariately investigated using
the log-rank test.
RESULTS
Patient characteristics
A total of 50 patients from three institutions were enrolled in this
study between 7 September 2004 and 3 March 2007. The median
follow-up duration was 8.9 months. Patient characteristics are
listed in Table 1.
Treatment administration
A total of 348 cycles were administered. Median number of cycles
delivered was 6 (range, 1–18). Dose modification for toxicities was
required in 25 (50%) of patients. Gemcitabine dose was reduced in
20 (40%) and capecitabine in 13 (26%) patients. Reasons for
treatment discontinuation are described in Table 2.
Toxicities
Haematological toxicities were common (Table 3). There were no
cases of febrile neutropaenia. Grade 3 or 4 non-haematologic
toxicities included two cases of diarrhoea and hand–foot
syndrome secondary to capecitabine and two cases with liver
function abnormalities, most likely related to biliary stent
occlusion. Bevacizumab-related toxicities were hypertension,
haemorrhage and thrombosis (Table 4). Most of the bleeding
events were grade 1 or 2 in severity and included epistaxis (n¼3)
or lower gastrointestinal bleeding events (n¼3). There were three
cases of grade 3 haemorrhage, all of which were gastrointestinal.
There was one case of grade 5 haemorrhage. This patient had
cancer involvement of the gastric wall and varices. Subsequently,
the study was amended: all patients with gastric involvement
or varices were excluded. There were no subsequent grade 5
toxicities.
Table 1 Patient characteristics
Characteristic Number Range Percentage
Total 50 — 100
Median age (years) 64 38–83 —
Sex: males 28 — 56
Stage:
locally advanced 3 — 6
metastatic 47 — 94
Prior surgical resection and adjuvant
therapy
5—1 0
Median CA 19-9 level 963Uml
 1 9.3–
1089979Uml
 1
Sites of metastases (measurable):
Liver 28 — —
Distant lymph node 2 — —
Lung 4 — —
Intra-abdominal 11 — —
Table 2 Reasons for treatment discontinuation
Reason Frequency (%)
Completed 1 year of bevacizumab 1 (2)
Disease progression 24 (48)
Toxicity 18 (36)
Death while on treatment 4 (8)
Other
a 3 (6)
aOne had symptomatic deterioration, one had open wounds and one was at
discretion of investigator.
Table 3 Treatment-related grade 3 or 4 toxicities
Toxicity Grade 3 Grade 4
Hematologic
Anaemia 3 0
Neutropaenia 11 0
Thrombocytopaenia 5 2
Non-hematologic
Fever 1 0
Fatigue 1 1
Diarrhoea 2 0
Hand–foot syndrome 2 0
Liver enzyme elevation (AST/ ALT) 4 0
Oedema 2 0
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All 50 patients were included in an intention-to-treat survival and
response analysis. The radiological responses were independently
confirmed by the Response Review Committee. A 22% RR
(PRþCR) was recorded in this trial. The median PFS was 5.8
months and the median OS was 9.8 months (Figure 1 and 2;
Table 5).
A 50% decline in CA 19-9 levels was seen in a larger number of
patients (65%). There was a statistically significant correlation
between 50% CA 19-9 decline and PFS (Po0 . 0 0 0 1 ,l o g - r a n kt e s t ) ,O S
(P¼0.0008, log-rank test) and response (P¼0.0069, exact w
2-test).
DISCUSSION
The majority of patients with pancreatic cancer have metastatic
disease at diagnosis and their survival has not significantly
changed over the past two decades (Baxter et al, 2007). Patients
who have a poor PS derive a marginal benefit from systemic
chemotherapy. The addition of bevacizumab to this combination
was based on preclinical and clinical data available at the time this
study was instituted (Chen, 2004; Kindler et al, 2005b). The dosage
of bevacizumab used was 15mgkg
 1, which was proven as
effective in combination with systemic chemotherapy for non-
small-cell lung cancer (Sandler et al, 2006). The bevacizumab-
related toxicities noted in this study were manageable and similar
to those reported at lower doses of this agent (Hurwitz and Saini,
2006). The study permitted administration of bevacizumab for a
maximum of 12 months as there was no safety data beyond that
duration. CA 19-9 decline was a useful surrogate marker for
response, PFS and OS in the present study. Similar results have
been reported by others (Halm et al, 2000; Ko et al, 2005). We used
PFS as the primary study end point. Overall survival and RR are
more commonly used. In our study, imaging studies were
performed at 6-week intervals, adding to the robustness of the
PFS data. In a recent meta-analysis, improved PFS and not RR
correlated with an improvement in OS (Bria et al, 2007).
Furthermore, OS may be confounded by second-line therapy.
The Cancer and Leukemia Group B (CALGB) randomised phase
III study of gemcitabine±bevacizumab reported no survival
advantage with the addition of bevacizumab (Kindler et al,
2007). Another recent, randomised phase III study of gemcitabine,
erlotinib±bevacizumab for advanced pancreatic cancer did not
meet its primary end point of improved survival in the
bevacizumab arm (Van Cutsem et al, 2009). Based on the results
of our study and the above two studies, the role of bevacizumab
therapy in this disease appears to be questionable and we are not
proceeding with a phase III study. This does not however reflect
the role of anti-angiogenic strategies in pancreatic cancer, which
are worthy of further study.
We conclude that the combination of gemcitabine, capecitabine
and bevacizumab is active in pancreatic cancer. Future investi-
gational strategies should focus on the identification of subgroups
that may benefit from the addition of anti-angiogenic therapy for
pancreatic cancer.
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Table 4 Adverse events possibly related to bevacizumab
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
Hypertension 6 6 4 0
Proteinuria 0 1 1 0
Haemorrhage 3 4 3 0
Thrombosis 0 2 3 0
Headache 3 1 1 0
Myocardial infarct 0 0 0 1
One patient had grade 5 haemorrhage.
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Figure 1 PFS curve (red) with 95% CI (black).
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Figure 2 OS curve (red) with 95% CI (black).
Table 5 Clinical efficacy data
Efficacy parameter Value 95% CI
Radiologic responses
Partial response 10 (20%) —
Complete response 1 (2%) —
Stable disease 30 (60%) —
Progressive disease 5 (10%) —
Not evaluable
a 4 (8%) —
PFS 5.8 months 4.2–7.8 months
OS 9.8 months 8.3–11.9 months
1-year survival 35.5% 21.7–49.5%
1-year PFS 19% 9.4–31.6%
CA 19-9
50% improvement 31 (65%) 0.49–0.78
Median duration of improvement. 4.46 months —
PFS¼progression-free survival; OS¼overall survival.
aNot evaluable due to disease
progression clinically.
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